Compare Abeona Therapeutics Inc (ABEO) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Enbridge Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Enbridge Inc trades at $54.99 (market cap $120.14B). The key difference: Enbridge Inc is far larger — about 321.8× Abeona Therapeutics Inc's market cap, and Enbridge Inc pays a 5.11% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ENB | |
|---|---|---|
Market Cap | $373.32M | $120.14B |
Sector | Health | Energy |
52-Week High | $7.23 | $58.04 |
52-Week Low | $4.17 | $43.79 |
Enterprise Value | $228.22M | $200.94B |
Dividend Yield | — | 5.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Enbridge (ENB) trades at $55.05, up 1.79% for the day, with a bearish technical signal from moving averages. The company reported strong revenue growth to $65.19B in 2025 and a net income margin of 10%, though it missed Q3 2025 EPS estimates. Recent news highlights include a dividend payment of $0.97 and upcoming Q2 2026 earnings on July 31, 2026. Analyst consensus is split evenly between Buy and Hold ratings.
Outlook remains mixed with solid cash flow from operations supporting dividends, but debt levels have risen to 48.81% of assets. Key risks include energy market volatility and execution of growth projects. The stock offers a high yield but faces near-term technical pressure and valuation concerns at a P/E of 25.73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
